CFO – Rhythm Pharma

Hunter Smith has been Chief Financial Officer of Rhythm Pharmaceuticals since August 2017, and served as interim Chief Executive Officer from March to July 2020. Since joining Rhythm, Hunter led the company’s initial public offering and subsequently raised additional capital totaling over $1 billion. As a member of Rhythm’s executive leadership team, Hunter has played a critical role in charting Rhythm’s corporate strategy and enabling its growth and development. He has over 30 years’ of leadership experience in global finance and management roles across multiple industries, functional disciplines, and geographic regions. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for operations in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited. Hunter previously served on the Board of Directors of Aeglea BioTherapeutics, Inc. and chaired its Audit Committee, until its merger with Spyre Therapeutics in 2023. He also previously served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation and Governance Committees, from 2015 until its acquisition by Brookfield Infrastructure Partners in December 2019. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University.